Health Care • Biotechnology: Laboratory Analytical Instruments
$4.84 ▼ -0.41
(-7.81%)
MKT CAP: $11.1M • VOL: 17.9K
52W L $2 52W H $69
ROARABLE / RQD
E • 28/100
PIOTROSKI
3 / 9
ASTC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.0M | $1.7M | $750.0K |
| YoY Revenue Growth % | -41.2% | +126.7% | — |
| Gross Profit | $475.0K | $751.0K | — |
| Gross Margin % | 47.5% | 44.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$14.7M | -$13.3M | -$11.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$13.8M | -$11.7M | -$9.6M |
| EBITDA (Normalized) | -$14.1M | -$12.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.0M | -$9.7M | -$7.6M |
| Capital Expenditures (CapEx) | $833.0K | $579.0K | — |
| Free Cash Flow (FCF) | -$13.8M | -$10.3M | -$7.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -37.3% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $15.5M | $28.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ASTC.